Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis
Jörn Karhausen, … , Sean P. Colgan, Volker H. Haase
Jörn Karhausen, … , Sean P. Colgan, Volker H. Haase
Published October 15, 2004
Citation Information: J Clin Invest. 2004;114(8):1098-1106. https://doi.org/10.1172/JCI21086.
View: Text | PDF
Article Cell biology

Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis

  • Text
  • PDF
Abstract

Mucosal epithelial cells are uniquely equipped to maintain barrier function even under adverse conditions. Previous studies have implicated hypoxia in mucosal tissue damage resulting from both acute and chronic inflammation. Given the importance of the transcriptional regulator hypoxia-inducible factor-1 (HIF-1) for adaptive hypoxia responses, we hypothesized that HIF-1 may serve as a barrier-protective element during mucosal inflammation. Initial studies of hapten-based murine colitis revealed extensive mucosal hypoxia and concomitant HIF-1 activation during colitis. To study this in more detail, we generated 2 mouse lines with intestinal epithelium–targeted expression of either mutant Hif1a (inability to form HIF-1) or mutant von Hippel-Lindau gene (Vhlh; constitutively active HIF-1). Studies of colitis in these mice revealed that decreased HIF-1 expression correlated with more severe clinical symptoms (mortality, weight loss, colon length), while increased HIF levels were protective in these parameters. Furthermore, colons with constitutive activation of HIF displayed increased expression levels of HIF-1–regulated barrier-protective genes (multidrug resistance gene-1, intestinal trefoil factor, CD73), resulting in attenuated loss of barrier during colitis in vivo. Taken together, these studies provide insight into tissue microenvironmental changes during model inflammatory bowel disease and identify HIF-1 as a critical factor for barrier protection during mucosal insult.

Authors

Jörn Karhausen, Glenn T. Furuta, John E. Tomaszewski, Randall S. Johnson, Sean P. Colgan, Volker H. Haase

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Epithelial hypoxia in TNBS colitis is associated with inflammatory lesio...
Epithelial hypoxia in TNBS colitis is associated with inflammatory lesions. (A) H&E staining in TNBS colitis (7 days after induction). In an area of relatively minor epithelial inflammation, submucosal vessels are encircled by a mixed population of inflammatory cells (filled arrow). Fibrinoid necrosis of the vessel walls (open arrow, with apoptotic bodies) and signs of luminal obliteration are observed. Magnification, ×600. (B) Localization of EF5 (nuclear counterstaining with DAPI) in a colonic section from a vehicle-control animal at day 3. Discrete immunofluorescence in surface epithelial cells and underlying crypts. (C) Corresponding phase-contrast image. Inset: H&E stain of an adjacent section. (D and E) Section taken from distal colon in TNBS-exposed animals. (D) Intense EF5 immunofluorescence overlying the area of ulceration (open arrow) and in underlying epithelial portions (filled arrow). (E) Phase contrast of D. Inset: H&E staining of an adjacent section from the same tissue, displaying erosion of the epithelial layer and beginning inflammatory infiltration. (F) Competed stain (section adjacent to that shown in D and E). Antibody specificity is documented by absence of Cy3 signal when antibody was saturated with free drug. (G) Corresponding phase-contrast image. Magnification in B–G, ×400. (H) HIF-1α stabilization in TNBS colitis. Western blot analysis from TNBS and vehicle-control (Ctl) animals 7 days after induction of colitis. Blots are derived from nuclear extracts from the colon of control and TNBS-treated animals. (I) Western blot analysis of the HIF-1–responsive genes ITF, P-GP, and GLUT-1 in control and TNBS-treated animals.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts